IP Library Granted Patent US 10,940,240
Granted Patent B2
US 10,940,240 · App. 15/425,436 · Granted Mar 9, 2021

Catheter locking solution and catheter locking therapy

Inventors: Premkumar Babu (Lansdale, PA); Benjamin R. Brozanski (Philadelphia, PA); Lisa Pagano (Pottstown, PA); Jeffrey S. Bennett (Pottstown, PA)
Assignee: Medical Components, Inc.
A61L29/16A61L2/0088A61L29/14A61L33/00A61L2300/21A61L2300/216A61L2300/404A61L2300/42A61M25/0017A61M2025/0019
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,940,240
App. No.
15/425,436
Granted
Mar 9, 2021
Kind
B2
Abstract

Various embodiments relate to catheter locking solutions and catheter locking therapies with use of trisodium citrate and ethyl alcohol, and in particular 4.0 to 15.0 weight/volume % trisodium citrate as an anticoagulant component and/or an antibacterial component and 15.0 to 25.0 volume/volume % ethyl alcohol as an antibacterial component. Use of the catheter locking solution and catheter locking therapy can reduce treatment failure during medical procedures that may employ catheters to supply treatment by at least significantly reducing the risks associated with bloodstream infections, catheter system malfunction, emboli formation, patient discomfort, and patient illness. These benefits can be partially due to the synergistic antibacterial effects of the trisodium citrate and ethyl alcohol in solution, generating an effective catheter locking solution with minimal concentrations of ethyl alcohol.

Claims (28)

1. A method of treating for biofilm, comprising:

introducing a solution consisting 4 to 10 weight/volume % (“w/v %”) trisodium citrate and 25 volume/volume % (“v/v %”) ethyl alcohol to a targeted environment; and,

maintaining contact between the solution and the targeted environment to at least one of prevent biofilm generation and eradicate biofilm that has been generated at the targeted environment; and,

wherein the targeted environment is free from trisodium citrate precipitation.

2. The method according to claim 1 , wherein the maintaining contact step is capable of generating a sterile targeted environment that is blood coagulant free.

3. The method according to claim 1 , wherein the solution exhibits a pH within a range from 4.0 to 8.0.

4. The method according to claim 1 , wherein the targeted environment is at least a portion of a catheter system.

5. The method according to claim 4 , wherein the maintaining contact step is capable of preventing thrombus formation within the catheter system.

6. The method according to claim 4 , further comprising flushing the at least the portion of the catheter system before introducing the solution.

7. The method according to claim 4 , further comprising applying positive pressure within the at least the portion of the catheter system during at least one of before the introducing step and after the maintaining contact step.

8. The method according to claim 1 , further comprising aspiration of the solution after the maintaining contact step.

9. The method according to claim 1 , further comprising at least one of:

allowing at least a portion of the solution to enter a bloodstream of a patient after the maintaining contact step; and

forcing at least a portion of the solution to enter the bloodstream of the patient after the maintaining contact step; and,

wherein the entrance of the solution into the bloodstream does not pose a toxicity risk to the patient.

10. The method according to claim 1 , further comprising renewing the solution after a predetermined period of time has elapsed during the maintaining contact step.

11. An aqueous catheter locking solution, consisting of:

4 to 10 weight/volume % (“w/v %”) of trisodium citrate;

25.0 volume/volume % (“v/v %”) of ethyl alcohol; and

water.

12. An aqueous catheter locking solution, consisting of:

10 weight/volume % (“w/v %”) of trisodium citrate;

25 volume/volume % (“v/v %”) of ethyl alcohol; and

water.

13. An aqueous catheter locking solution, consisting of:

4 weight/volume % (“w/v %”) of tri sodium citrate;

25 volume/volume % (“v/v %”) of ethyl alcohol; and

water.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 28, 2018
From: BABU, PREMKUMAR; BROZANSKI, BENJAMIN R.; PAGANO, LISA; BENNETT, JEFFREY S.
To: MEDICAL COMPONENTS, INC.
Reel/Frame 046224/0032 →
Continuity (2)
Provisional Application 62294478 · Feb 12, 2016
Related Publication 20170232153A1 · Aug 17, 2017
Cited By (1)
US 12,285,573